AR047681A1 - Compuestos indazol-carboxamida como agonistas del receptor 5-ht4 - Google Patents

Compuestos indazol-carboxamida como agonistas del receptor 5-ht4

Info

Publication number
AR047681A1
AR047681A1 ARP050100560A ARP050100560A AR047681A1 AR 047681 A1 AR047681 A1 AR 047681A1 AR P050100560 A ARP050100560 A AR P050100560A AR P050100560 A ARP050100560 A AR P050100560A AR 047681 A1 AR047681 A1 AR 047681A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
optionally substituted
compounds
cycloalkyl
Prior art date
Application number
ARP050100560A
Other languages
English (en)
Inventor
Daniel Marquess
Seok-Ki Choi
Paul R Fatheree
Roland Gendron
Adam Goldblum
Daniel D Long
S Derek Turner
Jyanwei Liu
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886184&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047681(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR047681A1 publication Critical patent/AR047681A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Abstract

Compuestos de indazol-carboxamida como agonistas del receptor 5-HT4. La presente también provee composiciones farmacéuticas que comprenden tales compuestos, métodos que utilizan tales compuestos para tratar enfermedades asociadas con la actividad del receptor 5-HT4, y procesos intermediarios utiles para preparar tales compuestos. Reivindicacion 1: Un compuesto de la formula (1), donde: R1 es hidrogeno, halo, hidroxi, alquilo C1-4, o alcoxi C1-4; R2 es alquilo C3-4, o cicloalquilo C3-6; y W se selecciona entre i) un grupo de la formula (2), en donde X es: NC(O)Ra, en donde Ra es alquilo C1-3 o tetrahidrofuranilo, en donde alquilo C1-3 está opcionalmente sustituido con -OH o alcoxi C1-3; S(O); o NS(O)2Rb, en donde Rb es metilo, opcionalmente sustituido con -OH, alcoxi C1-3, cicloalquilo C5-6, o -S(O)2-alquilo C1-3; ii) un grupo de la formula (3), donde: Ry es -OH o alcoxi C1-3; p es 0 o 1; n es 1 o 2; y Y es: NRcC(O)Rd, en donde Rc es hidrogeno o alquilo C1-3 y Rd es alquilo C1-3 opcionalmente sustituido con -OH o alcoxi C1-3; o NReS(O)2RF, en donde Re es hidrogeno y Rf es alquilo C1-3 opcionalmente sustituido con -OH, alcoxi C1-3, cicloalquilo C5-6, o -S(O)2-alquilo C1-3; y iii) un grupo de la formula (4), donde: Rz es hidrogeno, alquilo C1-3, o alquilo C2-3 sustituido con -OH o alcoxi C1-3; m es 1 o 2; q es 1 o 2, con la salvedad de que la suma de m y q no sea igual a 4; y Z es NRC(O)Rg, en donde Rg es alquilo C1-3, opcionalmente sustituido con -OH o alcoxi C1-3; S(O)2; o NS(O)2Rh, en donde Rh es metilo, opcionalmente sustituido con -OH, alcoxi C1-3, cicloalquilo C5-6, o -S(O)2-alquilo C1-3; o una sal o un solvato o un estereoisomero aceptable para uso farmacéutico del mismo.
ARP050100560A 2004-02-18 2005-02-17 Compuestos indazol-carboxamida como agonistas del receptor 5-ht4 AR047681A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54570204P 2004-02-18 2004-02-18

Publications (1)

Publication Number Publication Date
AR047681A1 true AR047681A1 (es) 2006-02-01

Family

ID=34886184

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100560A AR047681A1 (es) 2004-02-18 2005-02-17 Compuestos indazol-carboxamida como agonistas del receptor 5-ht4

Country Status (16)

Country Link
US (3) US7351704B2 (es)
EP (1) EP1718643A1 (es)
JP (1) JP2007523175A (es)
KR (1) KR20060132727A (es)
CN (1) CN1922175A (es)
AR (1) AR047681A1 (es)
AU (1) AU2005214368A1 (es)
BR (1) BRPI0507791A (es)
CA (1) CA2553696A1 (es)
IL (1) IL177059A0 (es)
MA (1) MA28435B1 (es)
NO (1) NO20064156L (es)
RU (1) RU2006133320A (es)
TW (1) TW200533348A (es)
WO (1) WO2005080389A1 (es)
ZA (1) ZA200606479B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
ES2327142T3 (es) * 2004-11-05 2009-10-26 Theravance, Inc. Compuestos de quinolinona-carboxamida.
EP1807422B1 (en) * 2004-11-05 2009-09-02 Theravance, Inc. 5-ht4 receptor agonist compounds
MX2007007818A (es) * 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
US20060183901A1 (en) * 2005-02-17 2006-08-17 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
KR20070107807A (ko) * 2005-03-02 2007-11-07 세라밴스 인코포레이티드 5-ｈｔ4 수용체 아고니스트인 퀴놀리논 화합물
ES2359673T3 (es) * 2005-06-07 2011-05-25 Theravance, Inc. Compuestos de benzoimidazolona-carboxamida como agonista del receptor 5-ht4.
JP2009513677A (ja) * 2005-10-25 2009-04-02 スミスクライン・ビーチャム・コーポレイション 化合物
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
MX2008010555A (es) * 2006-02-16 2008-09-15 Theravance Inc Proceso para preparar intermediarios de compuestos agonistas de receptor de 5-ht4.
KR100812499B1 (ko) * 2006-10-16 2008-03-11 이도훈 항경련제
ES2536404T3 (es) * 2007-02-23 2015-05-25 K.H.S. Pharma Holding Gmbh Procedimiento para la preparación de ésteres de azoniaspironortropina
CN101910169A (zh) 2008-02-13 2010-12-08 卫材R&D管理有限公司 双环胺衍生物
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
MX343165B (es) * 2010-02-12 2016-10-26 Raqualia Pharma Inc Agonistas del receptor 5-ht4 para el tratamiento de demencia.
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
AU2012267797A1 (en) * 2011-06-07 2014-01-09 Sumitomo Dainippon Pharma Co., Ltd. Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
EA201491990A1 (ru) 2012-05-03 2015-02-27 Новартис Аг L-малатная соль 2,7-диазаспиро[4.5]дец-7-иловых производных и их кристаллические формы в качестве агонистов грелиновых рецепторов
JP2014133739A (ja) * 2012-12-12 2014-07-24 Dainippon Sumitomo Pharma Co Ltd インダゾール誘導体またはピロロピリジン誘導体からなる医薬
NZ728918A (en) * 2014-08-16 2018-05-25 Suven Life Sciences Ltd Process for large scale production of 1-isopropyl-3-{ 5-[1-(3-methoxypropyl)piperidin-4-yl]-[1,3,4]oxadiazol-2-yl} -1h-indazole oxalate
WO2021046789A1 (zh) * 2019-09-12 2021-03-18 广东东阳光药业有限公司 吲唑-甲酰胺衍生物及其用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321378A (en) * 1979-01-16 1982-03-23 Delalande S.A. 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
HU202108B (en) * 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
DE3777805D1 (de) * 1986-11-21 1992-04-30 Glaxo Group Ltd Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
IT1226389B (it) * 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
EP0410509A1 (en) * 1989-07-25 1991-01-30 Duphar International Research B.V New substituted 1H-indazole-3-carboxamides
JPH045289A (ja) 1990-04-24 1992-01-09 Hokuriku Seiyaku Co Ltd アミド化合物
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
CA2097815C (en) * 1990-12-28 2001-04-17 Fumio Suzuki Quinoline derivative
WO1993003725A1 (en) 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
WO1993005040A1 (en) * 1991-09-12 1993-03-18 Smithkline Beecham Plc Azabicyclic compounds as 5-ht4 receptor antagonists
MX9305947A (es) * 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
WO1994012497A1 (en) * 1992-11-20 1994-06-09 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
TW251287B (es) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
KR970701191A (ko) * 1994-02-28 1997-03-17 우에하라 아키라 복소환 화합물
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
US5684003A (en) * 1994-10-20 1997-11-04 Nisshin Flour Milling Co., Ltd. 5-HT4 receptor agonists
JP3829880B2 (ja) 1994-12-27 2006-10-04 大正製薬株式会社 化学中間体
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
WO1996038420A1 (fr) * 1995-05-31 1996-12-05 Nisshin Flour Milling Co., Ltd. Derives de l'indazole a groupe amino monocyclique
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
TW548103B (en) * 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US5914405A (en) * 1997-10-07 1999-06-22 Eli Lilly And Company Process for preparing 3-substituted indazoles
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
FR2769915B1 (fr) 1997-10-21 2000-10-13 Synthelabo Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
IT1298271B1 (it) 1998-02-18 1999-12-20 Boehringer Ingelheim Italia Esteri ed ammidi dell'acido 2-oxo-2,3-diidro-benzimidazol-1- carbossilico
ATE283260T1 (de) * 1998-04-28 2004-12-15 Dainippon Pharmaceutical Co 1-(1-subst.-4-piperidinyl)methyl)-4-piperidin- derivate, verafhren zu deren herstellung, pharmazeutische mixturen und intermediate zu deren herstellung
DE69935600T2 (de) * 1998-09-10 2007-12-06 F. Hoffmann-La Roche Ag Dihydrobenzodioxincarbonsäureamid- und ketonderivate als 5-ht4-rezeptorantagonisten
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
FR2792318B1 (fr) 1999-04-16 2001-06-15 Synthelabo Derives d'indazole, leur preparation et leur application en therapeutique
JP2002542287A (ja) * 1999-04-28 2002-12-10 レスピラトリウス アクチボラゲット 医 薬
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
IT1313660B1 (it) 1999-10-01 2002-09-09 Dompe Spa Procedimento stereoselettivo per la preparazione di endo-3-amminoazabicicloalcani.
AU2002212888A1 (en) 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
AP1789A (en) 2002-04-08 2007-10-05 Pfizer Tropane derivatives useful in therapy.
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
EP1543004A1 (en) * 2002-09-20 2005-06-22 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
DOP2003000703A (es) * 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
CA2523077A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
EP2305254A1 (en) 2003-06-19 2011-04-06 Janssen Pharmaceutica NV Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists for the treatment of gatrointestinal conditions
JP3983269B1 (ja) 2003-09-03 2007-09-26 ファイザー株式会社 ５−ｈｔ４受容体作動活性を有するベンズイミダゾロン化合物
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
US7691881B2 (en) 2004-01-29 2010-04-06 Pfizer Inc 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
EP1807422B1 (en) * 2004-11-05 2009-09-02 Theravance, Inc. 5-ht4 receptor agonist compounds

Also Published As

Publication number Publication date
RU2006133320A (ru) 2008-03-27
IL177059A0 (en) 2006-12-10
CN1922175A (zh) 2007-02-28
ZA200606479B (en) 2008-01-30
US7674908B2 (en) 2010-03-09
BRPI0507791A (pt) 2007-07-17
US8044045B2 (en) 2011-10-25
TW200533348A (en) 2005-10-16
JP2007523175A (ja) 2007-08-16
CA2553696A1 (en) 2005-09-01
US20100261716A1 (en) 2010-10-14
US20050197335A1 (en) 2005-09-08
NO20064156L (no) 2006-11-10
WO2005080389A1 (en) 2005-09-01
AU2005214368A1 (en) 2005-09-01
US7351704B2 (en) 2008-04-01
KR20060132727A (ko) 2006-12-21
EP1718643A1 (en) 2006-11-08
US20080146807A1 (en) 2008-06-19
MA28435B1 (fr) 2007-02-01

Similar Documents

Publication Publication Date Title
AR047681A1 (es) Compuestos indazol-carboxamida como agonistas del receptor 5-ht4
AR050407A1 (es) Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
AR072162A1 (es) Compuestos de ester boronato y composiciones farmaceuticas de los mismos
UY29479A1 (es) Inhibidores de adn-pk
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
CO5650257A2 (es) Derivados de pirazol [1,5-a]pirimidina
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
MX2009000475A (es) Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas.
HN2010001059A (es) Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes.
MX346367B (es) Derivado de triazina y composicion farmaceutica que tiene actividad analgesica que comprende el mismo.
PT1910381E (pt) Compostos substituídos de 1-oxa-3,8-diazaspiro[4.5]decan-2- ona e sua utilização para produção de fármacos
BRPI0510716A (pt) uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
NO20071880L (no) Diagnostic Compounds
PE20110845A1 (es) Nuevos compuestos heterociclicos nitrogenados, preparacion de los mismos y utilizacion de los mismos como medicamentos antibacterianos
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
AR046322A1 (es) Compuestos de amidoacetonitrilo, metodos para su preparacion y de sus intermediarios y su uso en composiciones antiparasitarias.
AR044883A1 (es) Derivados del 8-aza-biciclo [3.2.1] octano y su uso como inhibidores de la recaptacion de neurotransmisores monoaminicos
PE20110207A1 (es) Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes
AR086573A2 (es) Derivados de 5-(piridin-3-il)-1-azabiciclo[3,2,1]octano y octeno, su preparacion y su aplicacion en terapeutica
ES2328496T3 (es) Compuestos de 1,4,8-triaza-espiro(4,5)decan-2-ona sustituidos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure